DB-1317 for selected advanced or metastatic solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a first-in-human, multicenter Phase 1a/1b trial using an accelerated titration then BOIN dose-escalation design to find the maximum or maximum administered dose and assess safety. DB-1317 will be given every three weeks with a 21-day DLT observation period in Cycle 1 and staggered dosing early in each escalation level for safety. After dose escalation, up to three expansion cohorts (one randomized and two single-arm) will further evaluate safety, tolerability, and preliminary anti-tumor activity to identify a recommended Phase 2 dose. Participants must provide tumor tissue or undergo biopsy for ADAM9 expression and other biomarker analyses when feasible.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Male or female adults
2. Unresectable advanced or metastatic selected solid tumors that have relapsed or progressed on or after standard systemic treatments.
3. Only applicable to backfilling participants in Phase 1a and participants in Phase 1b: At least one measurable lesion as assessed by the investigator according to RECIST version 1.1 criteria. Participants with non-measurable disease are allowed for CRPC participants.
4. Has a life expectancy of ≥ 3 months.
5. Has an ECOG PS of 0-1.
6. Has LVEF ≥ 50% within 28 days before enrollment.
7. Is willing to provide pre-existing resected tumor samples or undergo fresh tumor biopsy for the measurement of ADAM9 expression level and other biomarkers if no contra-indication.
8. Male and female participants of reproductive/childbearing potential must agree to use adequate contraceptive methods

Key Exclusion Criteria:

1. Prior treatment with ADAM9 targeted therapy.
2. Prior treatment with antibody-drug conjugate with topoisomerase I inhibitor.
3. Has a medical history of symptomatic congestive heart failure or serious cardiac arrhythmia requiring treatment.
4. Has a medical history of myocardial infarction or unstable angina within 6 months before enrollment.
5. Has any clinically important abnormalities in rhythm, conduction or morphology of resting ECG
6. Has an average of Fredericia's formula-QT corrected interval (QTcF) prolongation to \> 470 ms in males and females
7. Has a history of (non-infectious) ILD/pneumonitis
8. Has a lung-specific intercurrent clinically significant illness
9. Has an uncontrolled infection requiring intravenous injection of antibiotics, antivirals, or antifungals.
10. Known human immunodeficiency virus (HIV) infection;Chronic, active, or uncontrolled hepatitis B;
11. Known chronic, active, or uncontrolled hepatitis C
12. Has clinically significant corneal disease.
13. Has clinically active brain metastases
14. Has unresolved toxicities from previous anticancer therapy Concurrent malignancy \< 3 years.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Where it's running

• Usa04-0
  Los Angeles, California, United States Recruiting
• Usa05-0
  Ann Arbor, Michigan, United States Recruiting
• Site USA06-0
  Pittsburgh, Pennsylvania, United States Recruiting
• Usa02-0
  Houston, Texas, United States Recruiting
• Usa03-0
  San Antonio, Texas, United States Recruiting
• Usa01-0
  Fairfax, Virginia, United States Recruiting

Study contacts

• Study coordinator: Junhua Gao
• Email: junhua.gao@dualitybiologics.com
• Phone: 01067228087

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HLX316 first-in-human dose study in advanced/metastatic solid tumors

  A first-in-human, Phase 1 study tests HLX316 to see if it is safe and tolerable and to get early signs of how it behaves in the body and whether it shows any tumor-killing activity in adults with advanced solid tumors.

  Recruiting Phase 1 Shanghai Henlius Biotech · Chongqing and 4 other locations · NCT07541534

• HLX48 first-in-human safety study in advanced solid tumors

  This early-phase study tests HLX48 in adults with advanced/metastatic solid tumors to see if it is safe and how it behaves in the body.

  Recruiting at 2 sites Phase 1 Shanghai Henlius Biotech · North Ryde, New South Wales and 6 other locations · NCT07473726

• SYS6043 treatment for advanced or metastatic solid tumors

  We will test SYS6043, a B7‑H3‑targeted antibody‑drug conjugate, in adults with advanced or metastatic solid tumors who have progressed on or are intolerant of standard therapies.

  Recruiting Phase 1/2 CSPC Megalith Biopharmaceutical Co.,Ltd. · Beijing, Beijing Municipality · NCT07415863

• HLX37 treatment for advanced or metastatic solid tumors, including non-small cell lung cancer

  This trial tests HLX37, given alone or with chemotherapy, to see if it is safe and how the body handles it in adults with advanced or metastatic solid tumors including non-small cell lung cancer.

  Recruiting at 2 sites Early Phase 1 Shanghai Henlius Biotech · Shanghai and 1 other locations · NCT07274813

• MHB088C treatment for adults with advanced solid tumors

  This study will test MHB088C to see if it is safe and shows early signs of benefit in adults with advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Qilu Pharmaceutical Co., Ltd. · Beijing · NCT07102004

• PF-08046876 for people with advanced solid tumors

  This trial tests a new antibody–drug conjugate called PF-08046876 given by IV in adults with advanced bladder, lung, head and neck, esophageal, or pancreatic cancers to see if it is safe and how it affects tumors.

  Recruiting at 30 sites Phase 1 Pfizer · Duarte, California and 30 other locations · NCT07090499

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.